KLK3 and prostate carcinoma: Although there were PSA declines following magnetic hyperthermia, responses in the monotherapy trial were of limited extent and duration and therefore, a phase 2 trial is now recruiting patients with intermediate risk prostate cancer and is evaluating magnetic hyperthermia in combination with low dose rate brachytherapy (Johannsen et al., 2010).